B42.7 Disseminated sporotrichosis

Name of the Condition

• Disseminated sporotrichosis

Summary

Disseminated sporotrichosis is a fungal infection caused by the Sporothrix species, characterized by widespread systemic involvement beyond the skin and subcutaneous tissues. It occurs when the fungus spreads from the initial site of infection to multiple organs, including the bones, joints, or central nervous system. This form of sporotrichosis is more severe and typically affects individuals with weakened immune systems, leading to diverse clinical manifestations depending on the organs involved.

Causes

Disseminated sporotrichosis is caused by the Sporothrix fungus, which is found in soil, decaying vegetation, and plant matter. Infection begins when fungal spores enter the body through breaks in the skin or via inhalation. In immunocompromised individuals, the fungus can disseminate hematogenously or via lymphatic spread, leading to systemic disease. The progression to disseminated disease is often linked to impaired immune function, allowing the fungus to invade deeper tissues and organs.

Risk Factors

• Weakened immune systems, including those with HIV/AIDS, uncontrolled diabetes, or immunosuppressive therapy (e.g., chemotherapy, long-term corticosteroids).
• Advanced age or chronic illnesses that compromise immune response.
• Untreated or inadequately treated localized sporotrichosis, which may progress to dissemination.
• Occupational or recreational exposure to soil, plants, or organic matter, increasing the likelihood of initial infection.

Symptoms

• Multiple nodular or ulcerative skin lesions in non-contiguous areas.
• Systemic symptoms such as fever, weight loss, or fatigue.
• Organ-specific manifestations, including bone pain (if skeletal involvement), joint swelling, or neurological symptoms (e.g., headache, confusion) in severe cases.
• Respiratory symptoms (e.g., cough, shortness of breath) if pulmonary involvement occurs.

Diagnosis

Diagnosis of disseminated sporotrichosis involves a combination of clinical evaluation, laboratory testing, and imaging. Clinical assessment identifies widespread or atypical lesions, particularly in high-risk individuals. Laboratory confirmation includes culture of tissue samples (e.g., skin biopsies, blood, or respiratory specimens) to isolate the Sporothrix fungus. Histopathological examination of affected tissues may reveal fungal elements. Imaging studies (e.g., X-rays, CT scans) assess organ involvement, such as bone or pulmonary lesions. Serological tests or molecular assays (e.g., PCR) may support diagnosis in complex cases.

Treatment Options

Treatment for disseminated sporotrichosis typically requires systemic antifungal therapy, often with longer durations than localized disease. First-line agents include itraconazole or posaconazole for mild to moderate cases. Severe or life-threatening infections may necessitate intravenous amphotericin B, followed by step-down therapy with an oral azole. Immunosuppressed patients may require prolonged treatment to prevent relapse. Adjunctive therapies, such as surgical debridement of infected tissues, may be considered in specific cases. Close monitoring for treatment response and adverse effects is essential.

Prognosis and Follow-Up

Prognosis for disseminated sporotrichosis depends on the extent of organ involvement and the patient’s immune status. Early diagnosis and appropriate antifungal therapy improve outcomes, but disseminated disease carries a higher risk of complications. Follow-up involves regular clinical assessments to monitor lesion resolution, organ function, and treatment efficacy. Immunocompromised patients may require extended therapy and periodic testing to detect relapse. Long-term surveillance is recommended for those with persistent or recurrent infections.

Complications

• Chronic or progressive organ damage, particularly to bones, joints, or the central nervous system.
• Respiratory failure or sepsis in severe cases.
• Treatment-related adverse effects, such as hepatotoxicity from antifungal medications.
• Recurrence of infection, especially in individuals with ongoing immunosuppression.

Lifestyle & Prevention

• Avoid contact with soil, plants, or organic matter that may harbor the Sporothrix fungus, particularly if skin is broken.
• Wear protective clothing (e.g., gloves, long sleeves) during activities involving potential exposure (e.g., gardening, farming).
• Maintain good wound care to prevent fungal entry through cuts or abrasions.
• For immunocompromised individuals, minimize high-risk exposures and consult a healthcare provider about preventive measures.

When to Seek Professional Help

Seek medical attention if you experience:

• Widespread skin lesions or systemic symptoms (e.g., fever, weight loss) following potential exposure to the fungus.
• Persistent or worsening respiratory symptoms (e.g., cough, shortness of breath) in high-risk individuals.
• Signs of organ involvement, such as bone pain, joint swelling, or neurological changes.
• Recurrence of infection after completing treatment, especially if immunosuppressed.

Tips for Medical Coders

• Code B42.7 is specific to disseminated sporotrichosis and should be used when the condition involves systemic spread beyond the skin and subcutaneous tissues.
• Documentation should clearly indicate the extent of dissemination (e.g., organ involvement, multiple sites) to support code assignment.
• Differentiate disseminated sporotrichosis from localized forms (e.g., lymphocutaneous) by verifying the presence of widespread or atypical lesions and systemic symptoms.
• Ensure coding aligns with clinical findings and provider documentation to reflect the severity and scope of the infection.